Develops novel therapies for central nervous system (CNS) disorders. Now — the numbers.

The company closed last year at a loss: costs ran above sales. The picture changes only if spending is reined in.

Before the clock runs out, either sales must climb sharply or new money must come in. This is the most critical line in the whole picture.

This company is not turning a profit, so the market is pricing its sales instead: 17.8× for every dollar of annual revenue.

Against companies in its own sector, it looks cheaper than 44% of them.

Analysts' average target sits 28% above today's price.

We compared this company with its own sector across five subjects.

A score of 50 means class average.

Profit indicators sit around the sector average.

Clearly below the class average.

Clearly below the class average.

This grade is a blend: the profit side is strong, the sales tempo slow.

Clearly above the class average — a step short of the very top.

Valuation: The stock trades at a price that looks expensive next to its earnings; that can cap future returns.

Financial Strength: The cash-and-debt balance is thin; the buffer for hard times is slim.

On our five-subject report card, AXSM sits behind the class. A low grade doesn’t mean “doomed” — it means “big claim, small proof.”

The takeaway: AXSM has solid sales but closed last year at a loss. The road back to profit runs through spending discipline.

The total grade weighs these five subjects against the sector — it isn’t a simple average of the five.

Analysts’ average target sits above today’s price, yet the valuation grade (44/100) says the stock isn’t cheap.

Not covered, because the filings we hold do not carry it: the revenue breakdown.